• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment

tetano

Editor, Senior Moderator
Eur J Clin Microbiol Infect Dis. 2016 Nov 15. [Epub ahead of print]
[h=1]Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment.[/h] Kossyvakis A[SUP]1[/SUP], Mentis AA[SUP]1,[/SUP][SUP]2[/SUP], Tryfinopoulou K[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Pogka V[SUP]1[/SUP], Kalliaropoulos A[SUP]1[/SUP], Antalis E[SUP]6[/SUP], Lytras T[SUP]7,[/SUP][SUP]8,[/SUP][SUP]9[/SUP], Meijer A[SUP]10[/SUP], Tsiodras S[SUP]6[/SUP], Karakitsos P[SUP]11[/SUP], Mentis AF[SUP]12[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] There was an increase in severe and fatal influenza cases in Greece during the 2011-2015 post-pandemic period. To investigate causality, we determined neuraminidase (NA) inhibitor susceptibility and resistance-conferring NA and hemagglutinin (HA) mutations in circulating influenza type A viruses during the pandemic (2009-2010) and post-pandemic periods in Greece. One hundred thirty-four influenza A(H1N1)pdm09 and 95 influenza A(H3N2) viruses submitted to the National Influenza Reference Laboratory of Southern Greece were tested for susceptibility to oseltamivir and zanamivir. Antiviral resistance was assessed by neuraminidase sequence analysis, as well as the fluorescence-based 50 % inhibitory concentration (IC[SUB]50[/SUB]) method. Five influenza A(H1N1)pdm09 viruses (2.2 %) showed significantly reduced inhibition by oseltamivir (average IC[SUB]50[/SUB] 300.60nM vs. 1.19nM) by Gaussian kernel density plot analysis. These viruses were isolated from immunocompromised patients and harbored the H275Y oseltamivir resistance-conferring NA substitution. All A(H1N1)pdm09 viruses were zanamivir-susceptible, and all A(H3N2) viruses were susceptible to both drugs. Oseltamivir-resistant viruses did not form a distinct cluster by phylogenetic analysis. Permissive mutations were detected in immunogenic and non immunogenic NA regions of both oseltamivir- resistant and susceptible viruses in the post-pandemic seasons. Several amino acid substitutions in the HA1 domain of the HA gene of post-pandemic viruses were identified. This study indicated low resistance to NAIs among tested influenza viruses. Antiviral resistance emerged only in immunocompromised patients under long-term oseltamivir treatment. Sequential sample testing in this vulnerable group of patients is recommended to characterise resistance or reinfection and viral evolution.


PMID: 27848039 DOI: 10.1007/s10096-016-2809-3
[PubMed - as supplied by publisher]
 
Back
Top Bottom